Olga Latinovic

Olga S. Latinovic, PhD, MSc, MBA, MSc is an Adjunct Assistant Professor in the Department of Microbiology and Immunology at the Institute of Human Virology, affiliated with the University of Maryland School of Medicine. Her research focuses on novel antiretroviral therapy strategies targeting HIV-1 entry mechanisms via the CCR5 coreceptor, utilizing humanized mouse models to validate drug combinations for clinical translation.

• Education:
  • PhD, Lehigh University (2006)
  • Master of Science, Lehigh University (2001)
  • Master of Business Administration, University of Baltimore (2020)
  • Master of Science in Health Care, University of Baltimore (2020)

Research Interests: Dr. Latinovic investigates HIV-1 entry inhibition through CCR5-targeting drugs, focusing on minimizing side effects while enhancing therapeutic synergy. Her work spans in vivo model development, drug combination validation, and cross-disciplinary virology (including SARS-CoV-2 receptor analysis).

Scientific Contributions: Key studies include CCR5 population dynamics in humanized models (2022), cART intensification with CCR5 inhibitors (2021), and SARS-CoV-2 receptor expression in neuronal cells (2021). Earlier work explored FLSC IgG1 fusion proteins (2016) and Mycoplasma-DnaK oncogenicity (2018).